Gilead Sciences Inc Company Profile
✉ Email this page to a colleague
▶ Start for $1
Remove trial restrictions
What is the competitive landscape for GILEAD SCIENCES INC, and what generic alternatives to GILEAD SCIENCES INC drugs are available?
GILEAD SCIENCES INC has twenty-one approved drugs.
There are seventy-six US patents protecting GILEAD SCIENCES INC drugs.
There are one thousand nine hundred and ninety-nine patent family members on GILEAD SCIENCES INC drugs in sixty-three countries and three hundred and twenty-seven supplementary protection certificates in nineteen countries.
Summary for Gilead Sciences Inc
International Patents: | 1999 |
US Patents: | 76 |
Tradenames: | 17 |
Ingredients: | 17 |
NDAs: | 21 |
Drug Master File Entries: | 7 |
Patent Litigation for Gilead Sciences Inc: | See patent lawsuits for Gilead Sciences Inc |
Drugs and US Patents for Gilead Sciences Inc
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Gilead Sciences Inc | TYBOST | cobicistat | TABLET;ORAL | 203094-001 | Sep 24, 2014 | RX | Yes | Yes | 8,148,374*PED | See Plans and Pricing | Y | See Plans and Pricing | |||
Gilead Sciences Inc | VIREAD | tenofovir disoproxil fumarate | POWDER;ORAL | 022577-001 | Jan 18, 2012 | RX | Yes | Yes | See Plans and Pricing | See Plans and Pricing | |||||
Gilead Sciences Inc | EPCLUSA | sofosbuvir; velpatasvir | TABLET;ORAL | 208341-001 | Jun 28, 2016 | RX | Yes | Yes | 9,284,342*PED | See Plans and Pricing | Y | See Plans and Pricing | |||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for Gilead Sciences Inc
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
---|---|---|---|---|---|---|---|
Gilead Sciences Inc | VIREAD | tenofovir disoproxil fumarate | TABLET;ORAL | 021356-003 | Jan 18, 2012 | 6,043,230*PED | See Plans and Pricing |
Gilead Sciences Inc | BIKTARVY | bictegravir sodium; emtricitabine; tenofovir alafenamide fumarate | TABLET;ORAL | 210251-002 | Oct 7, 2021 | 7,803,788 | See Plans and Pricing |
Gilead Sciences Inc | ODEFSEY | emtricitabine; rilpivirine hydrochloride; tenofovir alafenamide fumarate | TABLET;ORAL | 208351-001 | Mar 1, 2016 | 6,838,464 | See Plans and Pricing |
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
Paragraph IV (Patent) Challenges for GILEAD SCIENCES INC drugs
Drugname | Dosage | Strength | Tradename | Submissiondate |
---|---|---|---|---|
➤ Subscribe | Tablets | 200 mg/25 mg/300 mg | ➤ Subscribe | 2015-05-20 |
➤ Subscribe | Tablets | 150 mg | ➤ Subscribe | 2015-12-09 |
➤ Subscribe | Tablets | 150 mg, 200 mg, and 250 mg | ➤ Subscribe | 2012-05-17 |
➤ Subscribe | Tablets | 150 mg, 150 mg, 200 mg, 300 mg | ➤ Subscribe | 2018-10-04 |
➤ Subscribe | Tablets | 300 mg | ➤ Subscribe | 2010-01-26 |
International Patents for Gilead Sciences Inc Drugs
Country | Patent Number | Estimated Expiration |
---|---|---|
Israel | 226345 | See Plans and Pricing |
South Korea | 20140037799 | See Plans and Pricing |
Philippines | 12014502862 | See Plans and Pricing |
>Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for Gilead Sciences Inc Drugs
Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
---|---|---|---|---|
3150586 | PA2020508,C3150586 | Lithuania | See Plans and Pricing | PRODUCT NAME: KOBICISTATAS ARBA FARMACINIU POZIURIU PRIIMTINA JO DRUSKA ARBA SOLVATAS, DARUNAVIRAS ARBA FARMACINIU POZIURIU PRIIMTINA JO DRUSKA ARBA SOLVATAS, YPAC DARUNAVIRO ETANOLATAS, IR EMTRICITABINAS, ARBA FARMACINIU POZIURIU PRIIMTINA JO DRUSKA ARBA SOLVATAS; REGISTRATION NO/DATE: EU/1/17/1225 20170921 |
1564210 | CR 2013 00058 | Denmark | See Plans and Pricing | PRODUCT NAME: ELVITEGRAVIR ELLER ET HYDRAT, ET SOLVAT, EN TAUTOMER ELLER ET FARMACEUTISK ACCEPTABELT SALT DERAF; REG. NO/DATE: EU/1/13/830/001-002 20130527 |
2822954 | C201830044 | Spain | See Plans and Pricing | PRODUCT NAME: BICTEGRAVIR O UNA SAL FARMACEUTICAMENTE ACEPTABLE DEL MISMO, EN PARTICULAR BICTEGRAVIR SODIO; NATIONAL AUTHORISATION NUMBER: EU/1/18/1289; DATE OF AUTHORISATION: 20180621; NUMBER OF FIRST AUTHORISATION IN EUROPEAN ECONOMIC AREA (EEA): EU/1/18/1289; DATE OF FIRST AUTHORISATION IN EEA: 20180621 |
>Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Here is a list of applicants with similar names.